Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading
radiopharmaceutical-focused company committed to enabling
clinicians to Find, Fight and Follow disease to deliver better
patient outcomes, today announced that the Company has appointed
Brian Markison, current Board Chair and industry veteran, to the
position of Chief Executive Officer (CEO), effective as of March 1,
2024. He will also continue as a member of Lantheus’ Board of
Directors, where he has served for the past 11 years. Mary Anne
Heino, who has successfully led and grown the Company for the past
nine years, will retire as CEO on March 1, 2024 and assume the role
of Chair of the Board of Directors as part of a deliberate CEO
succession process. As part of this leadership transition, Mr.
Markison will assume the role of Executive Chair of the Board
immediately until his CEO appointment in March, and Board Member
Julie McHugh will become Lead Independent Director effective
immediately.
“Brian is perfectly suited to lead Lantheus as the Company
enters its next phase of growth. He has held the Chair role for
more than 10 years and in that role has overseen Company strategy.
He knows our exceptional Executive Team well and brings decades of
leadership experience as the CEO of public companies with
development, commercialization and manufacturing expertise,
including in oncology and neurology therapeutics,” said Mary Anne
Heino. “It has been my honor to lead Lantheus over the past nine
years, and I am extremely proud of what we have accomplished. Our
leadership as a radiopharmaceutical-focused company and the
contributions Lantheus has made to precision diagnostics have aided
healthcare providers and their patients around the world. We have
an incredibly talented team at Lantheus, and I look forward to
serving as Chair and continuing to partner closely with Brian and
the Executive Team as we focus on our Purpose to Find, Fight and
Follow disease to deliver better patient outcomes.”
Mr. Markison has 40 years of healthcare experience, including
executive roles at King Pharmaceuticals, Fougera Pharmaceuticals
and RVL Pharmaceuticals plc, as well as senior level roles at
Bristol-Myers Squibb. Mr. Markison has maintained a steadfast focus
throughout his career on oncology, virology, and diagnostics,
leading the successful commercial introduction of numerous
therapeutics, ranging from chemotherapy to biologics, across major
global markets. He has been a member of the Lantheus Board of
Directors since September 2012 and has served as Chairman since
January 2013. Mr. Markison most recently served as CEO and Director
of RVL Pharmaceuticals plc, formerly Osmotica Holdings, SCSp. He
serves on the Board of Directors of Cosette Pharmaceuticals and is
a Director of the College of New Jersey.
“On behalf of the Lantheus Board of Directors, I would like to
sincerely thank Mary Anne for her remarkable leadership and
contributions that helped drive Lantheus’ success throughout her
tenure as CEO,” said Ms. McHugh. “We are energized by the
experience and expertise Brian brings to this role, and confident
in the Company’s ability to build on Mary Anne’s legacy by
strengthening its leading position in the industry and executing on
the compelling opportunities ahead.”
Under the leadership of Ms. Heino and the Executive Team,
Lantheus marked numerous achievements, establishing a strong
foundation for long-term growth. These included the development and
commercialization of the leading prostate-specific membrane antigen
(PSMA) targeted positron emission tomography (PET) imaging agent
for prostate cancer. She led the successful acquisition of
Progenics, expanding Lantheus’ lines of business from diagnostic
imaging agents to a diverse range of diagnostics, radiotherapeutics
and artificial intelligence solutions. Most recently, she executed
a strategic collaboration with POINT Biopharma, enhancing Lantheus’
radiopharmaceutical portfolio with two late-stage therapeutic
candidates; the acquisition of Cerveau Technologies, Inc.,
expanding the company’s imaging pipeline into Alzheimer’s disease;
and strategic agreements with Perspective Therapeutics, Inc., a
radiopharmaceutical company that is pioneering advanced treatment
applications for cancers throughout the body.
“I want to thank the Board of Directors for this tremendous
opportunity to lead Lantheus as CEO,” said Brian Markison.
“Lantheus has a dynamic team dedicated to delivering life-changing
science to patients and providers across the globe, and we are
poised to enhance our growth trajectory by unlocking the potential
of our innovative platform to improve patient outcomes and lives. I
could not be more pleased to make this transition from Chair to CEO
and lead the company as we execute on the many opportunities that
lie ahead.”
Preliminary Full Year 2023 Revenue
As previously announced on January 9, 2024, worldwide revenue
for the full year 2023 is expected to be in the range of $1.295 -
1.297 billion, which includes a $15 million RELISTOR milestone
achievement, compared with $0.935 billion for the full year 2022,
which would represent an increase of approximately 38 - 39% over
the prior year period, exceeding the Company’s previously issued
guidance range of $1.255 - 1.270 billion.
These preliminary results are unaudited and remain subject to
adjustment. Lantheus will provide its fourth quarter and full year
2023 financial results, and further details related to its 2024
financial expectations, in late February 2024.
About LantheusLantheus is the leading
radiopharmaceutical-focused company, delivering life-changing
science to enable clinicians to Find, Fight and Follow disease to
deliver better patient outcomes. Headquartered in Massachusetts
with offices in Canada and Sweden, Lantheus has been providing
radiopharmaceutical solutions for more than 65 years. For more
information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary
Statements This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks and
uncertainties and are made pursuant to the safe harbor provisions
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may be identified by their use of terms
such as “build,” “capture,” “continue,” “executing,” “expected,”
“guidance,” “poised,” “will,” “would” and other similar terms. Such
forward-looking statements are based upon current plans, estimates
and expectations that are subject to risks and uncertainties that
could cause actual results to materially differ from those
described in the forward-looking statements. The inclusion of
forward-looking statements should not be regarded as a
representation that such plans, estimates and expectations will be
achieved. Readers are cautioned not to place undue reliance on the
forward-looking statements contained herein, which speak only as of
the date hereof. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law. Risks and uncertainties that could cause our
actual results to materially differ from those described in the
forward-looking statements are discussed in our filings with the
Securities and Exchange Commission (including those described in
the Risk Factors section in our Annual Reports on Form 10-K and our
Quarterly Reports on Form 10-Q).
Contacts:Mark KinarneyVice President, Investor
Relations978-671-8842ir@lantheus.com
Melissa DownsSenior Director, External
Communications646-975-2533media@lantheus.com
Lantheus (NASDAQ:LNTH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Lantheus (NASDAQ:LNTH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024